Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) executives William A. Hartman and Dr. Mitchell S. Felder discussed transformative research milestones and their implications for healthcare during an interview on The Street Reports. They emphasized how their innovations could significantly impact the treatment of various diseases. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and has filed 22 additional patent applications to enhance stockholder value and attract development partners. For further updates, interested individuals can subscribe via the company's contact page.

Positive

• Secured exclusive worldwide rights to three issued patents.
• Filed 22 related provisional, PCT, or utility patent applications.
• Potential to revolutionize healthcare and treatment of various diseases.

Negative

• None.

JACKSON CENTER, PA / ACCESSWIRE / October 27, 2022 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," speaking about significant milestones which their research demonstrated, how it could revolutionize the healthcare sector and the potential effects it could have on the treatment of numerous diseases.

Listen here: https://thestreetreports.com/the-street-reports-podcast-features-halberd-corporations-otc-halb-ceo-william-hartman-and-chief-technology-officer-dr-mitchell-s-felder-listen-now/

To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/722570/Hartman-CEO-and-Dr-Felder-CTO-of-Halberd-Corp-Featured-on-The-Street-Reports-Podcast

FAQ

What is Halberd Corporation's recent announcement about?

Halberd Corporation's executives discussed significant research milestones that could revolutionize healthcare.

Who are the key figures interviewed in the Halberd Corporation announcement?

William A. Hartman (Chairman, President, and CEO) and Dr. Mitchell S. Felder (Chief Technology Officer) were interviewed.

What is the stock symbol for Halberd Corporation?

The stock symbol for Halberd Corporation is HALB.

What patents has Halberd Corporation secured?

Halberd has obtained exclusive worldwide rights to three issued patents.

How many patent applications has Halberd Corporation filed?

Halberd has filed 22 related provisional, PCT, or utility patent applications.